Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons

Numerous studies suggest that the dopamine transporter (DAT), responsible for dopamine reuptake, may act as a vulnerability factor in the pathogenesis of Parkinson's disease (PD) and the vesicular monoamine transporter (VMAT2), responsible for its vesicular storage, as a neuroprotective factor....

Full description

Saved in:
Bibliographic Details
Published inJournal of comparative neurology (1911) Vol. 479; no. 2; pp. 198 - 215
Main Authors González-Hernández, Tomás, Barroso-Chinea, Pedro, de la Cruz Muros, Ignacio, del Mar Pérez-Delgado, María, Rodríguez, Manuel
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 08.11.2004
Subjects
Online AccessGet full text
ISSN0021-9967
1096-9861
DOI10.1002/cne.20323

Cover

More Information
Summary:Numerous studies suggest that the dopamine transporter (DAT), responsible for dopamine reuptake, may act as a vulnerability factor in the pathogenesis of Parkinson's disease (PD) and the vesicular monoamine transporter (VMAT2), responsible for its vesicular storage, as a neuroprotective factor. However, the relevance of each on the differential vulnerability of midbrain DA cells remains uknown. Here we studied the relationship between the expression pattern (mRNA and protein) of both transporters and the differential vulnerability of midbrain DA cells in a model of PD (intracerebroventricular injection of 6‐OHDA in rats) and in monkey and human midbrain. Our results revealed that the expression patterns for VMAT2 mRNA and protein and DAT mRNA are similar, with the highest levels in the rostromedial region of substantia nigra (SNrm), followed by the caudoventral region of SN (SNcv), the ventral tegmental area and pigmented parabrabraquial nucleus (VTA/PBP), and finally the linear and interfascicular nuclei (Li/IF). In contrast, the expression of DAT protein in rats, monkeys, and humans followed a caudoventrolateral‐to‐rostrodorsomedial decreasing gradient (SNcv > SNrm > VTA/PBP > Li/IF), matching the degeneration profile observed after intracerebroventricular injection of 6‐OHDA and in PD. In addition, DAT blockade made all midbrain DA cells equally resistant to 6‐OHDA. These data indicate that DAT protein levels, but not DAT mRNA levels, are closely related to the differential vulnerability of midbrain DA cells and that this relationship is unaffected by the relative levels of VMAT2. Furthermore, the difference between DAT mRNA and protein profiles suggests internuclear differences in its posttransductional regulation. J. Comp. Neurol. 479:198–215, 2004. © 2004 Wiley‐Liss, Inc.
Bibliography:Centros de Investigación de Enfermedades Neurológicas
Fondo de Investigaciones Sanitarias - No. 01/1126
istex:4CBC1EE1CCA5122BB5B7D61EB852CBB6D60971CA
ark:/67375/WNG-NRBM8Q2D-L
ArticleID:CNE20323
Fundación Canaria de Investigación y Salud
Consejeria de Educación del Gobierno Autónomo de Canarias - No. PI2001/054
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0021-9967
1096-9861
DOI:10.1002/cne.20323